BTEC:LSE:LSE-iShares Nasdaq US Biotechnology UCITS ETF USD (Acc) (USD)

ETF | Others |

Last Closing

USD 6.4275

Change

+0.01 (+0.08)%

Market Cap

USD 0.45B

Volume

0.10M

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-03-28 )

Largest Industry Peers for Others

Symbol Name Price(Change) Market Cap
0R15:LSE SoftBank Group Corp.

N/A

USD 9,217.80B
0R1E:LSE Nintendo Co. Ltd.

N/A

USD 7,596.04B
0R1O:LSE Amazon.com Inc.

N/A

USD 1,607.29B
0R1I:LSE NVIDIA Corp.

N/A

USD 618.20B
LCJP:LSE Lyxor Core MSCI Japan (DR) UCI..

N/A

USD 617.54B
LCJD:LSE Amundi MSCI Japan (DR) UCITS E..

N/A

USD 617.54B
0R1G:LSE Home Depot Inc.

N/A

USD 373.16B
XDJP:LSE Xtrackers Nikkei 225 UCITS ETF..

N/A

USD 348.03B
0QZK:LSE Coca-Cola Co.

N/A

USD 266.08B
0QZO:LSE 0QZO

N/A

USD 258.54B

ETFs Containing BTEC:LSE

N/A

Market Performance

  Market Performance vs. Industry/Classification (Others) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 0.74% 34% F 43% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 0.74% 33% F 42% F
Trailing 12 Months  
Capital Gain 9.64% 51% F 58% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 9.64% 50% F 57% F
Trailing 5 Years  
Capital Gain 29.03% 50% F 61% D-
Dividend Return N/A N/A N/A N/A N/A
Total Return 29.03% 47% F 58% F
Average Annual (5 Year Horizon)  
Capital Gain 6.99% 63% D 67% D+
Dividend Return 6.99% 62% D 66% D+
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 19.85% 36% F 49% F
Risk Adjusted Return 35.20% 59% D- 70% C-
Market Capitalization 0.45B 68% D+ 58% F

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.